Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

The Top Ways to Ward Off Infection, according to Health Experts

Livemoney March 19, 2020

Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns

Business Wire March 18, 2020

Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch

Business Wire March 18, 2020

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older

Business Wire March 18, 2020

IDEAYA and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

PR Newswire March 18, 2020

Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts

Business Wire March 17, 2020

Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine

GlobeNewswire March 17, 2020

EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study

PR Newswire March 13, 2020

Merck and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study

PR Newswire March 13, 2020

New GeoMap Tools Get Patient Recruitment Back on Track During the COVID-19 Outbreak

ACN Newswire March 9, 2020

Susan Hockfield Elected to Pfizer's Board of Directors

Business Wire March 4, 2020

U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis

PR Newswire March 2, 2020

James Quincey Elected to Pfizer's Board of Directors

Business Wire February 27, 2020

Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer

Business Wire February 27, 2020

Mylan and Pfizer Finalize Appointments to Viatris Board of Directors

Business Wire February 27, 2020

Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer

Livemoney February 26, 2020

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire February 25, 2020

European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Business Wire February 18, 2020

XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC

PR Newswire February 11, 2020

Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE(TM) (rituximab)

Business Wire January 31, 2020